LI Caina
Associate professor, graduated from Shenyang Pharmaceutical University in 2006, and continued with her PhD study in Institute of Materia Medica, CAMS&PUMC and was awarded the PhD in 2011. She mainly worked on the pharmacological study of novel GLP-1-based drugs and mechanism study of the occurrence and development of diabetes. Up to now, she has been successful in obtaining four research funds, including two National Natural Science Foundations of China, and has completed the pharmacological studies of 3 novel long-acting GLP-1 receptor agonists and participated in the development of new drugs, Mulberry Twig Alkaloids Tablet and YR536. She established the experimental model and method to search active GLP-1 analogs that could resist intestinal degradation, so as to develop oral GLP-1 in combination with pharmaceutical preparation technology. She has published 14 articles as the first and correspondence author, including 8 articles included in SCI journals, and have taken part in application of 10 patents, assisted in training 7 postgraduates, and got 3 academic awards.
1. Berberine combined with stachyose induces better glycometablism than berberine alone through modulating gut microbiota and fecal metabolomics in diabetic mice. Phytother Res , 2020, 34(5): 1166-1174.
2. Stachyose improves the effects of berberine on glucose metabolism by regulating intestinal microbiota and short-chain fatty acids in spontaneous type 2 diabetic KKAy mice. Front Pharmacol , 2020, 11: 578943.
3. Effects of a ready-to-eat cereal formula powder on glucose metabolism, inflammation, and gut microbiota in diabetic db/db mice. Food Sci Nutr , 2020, 8(8): 4523-4533.
4. Glutazumab, a novel long-lasting GLP-1/anti-GLP-1R antibody fusion protein, exerts anti-diabetic effects through targeting dual receptor binding sites. Biochemical Pharmacology , 2018, 150: 46-53
5. Maltol, a food flavor enhancer, attenuates diabetic peripheral neuropathy in streptozotocin-induced diabetic rats. Food and Function . 2018, 9: 6287- 6297
6. A human glucagon-like peptide-1-albumin recombinant protein with prolonged hypoglycemic effect provides efficient and beneficial control of glucose metabolism in diabetic mice. Biol. Pharm. Bull. , 2017, 40: 1399-1408
7. The albumin-exendin-4 recombinant protein E2HSA improves glycemic control and β-cell function in spontaneous diabetic KKAy mice. BMC Pharmacology and Toxicology , 2017, 18: 48-56
8. The PI3K/Akt1-FoxO1 translocation pathway mediates Exf effects on NIT-1 cell survival. Exp Clin Endocrinol Diabetes. , 2017, 125: 669-676
9. Diphenyl diselenide ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats via suppressing oxidative stress and inflammation. Chemico-Biological Interactions . 2021, 338: 109427.
10. Diphenyl diselenide alleviates diabetic peripheral neuropathy in rats with streptozotocin-induced diabetes by modulating oxidative stress. Biochemical Pharmacology . 2020, 182: 114221.
11. Effects of E2HSA, a long-acting Glucagon like peptide-1 receptor agonist, on glycemic control and beta cell function in spontaneous diabetic db/db mice. Journal of Diabetes Research . 2015, 2015: 817839
12. A simple and stable galactosemic cataract model for rats. Int J Clin Exp Med. , 2015, 8(8): 12874-12881
13. Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins. Acta Pharmaceutica Sinica B. , 2014, 4(2): 135-140
14. Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress. Lipids in Health and Disease. , 2014, 13: 98-107
15. Long-term treatment with Exf, a peptide, analog of Exendin-4, improves β-cell function and survival in diabetic KKAy mice. Peptides , 2013, 40: 123-132
